Indian pharma companies may benefit under Trump 2.0
NEW DELHI: The Trump 2.0 agenda, with its likely focus on China plus 1 strategy for pharmaceutical manufacturing and supply...
NEW DELHI: The Trump 2.0 agenda, with its likely focus on China plus 1 strategy for pharmaceutical manufacturing and supply...